Want to see FR:AB full AI Analyst Report?
Top Page
AB Science SA
(AB)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.52
▲(1.76% Upside)
Action:Reiterated
Date:07/15/26
The score is primarily held down by weak financial fundamentals (ongoing losses, negative equity, and renewed cash burn). Technicals also remain bearish with the stock trading below all key moving averages and negative MACD, though oversold indicators slightly offset this. Valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Debt Reduction
A dramatic reduction in debt materially lowers interest and covenant pressure and improves financing optionality. Over a multi-month horizon this reduces near-term solvency risk, extends strategic runway for clinical programs, and makes non-dilutive partnership or licensing deals easier to negotiate.
Negative Factors
Persistent Negative Equity
Negative shareholder equity reflects cumulative losses and is a durable solvency red flag. Over 2–6 months it constrains access to capital, increases likelihood of dilutive financing or onerous terms, and limits the company's ability to absorb setbacks or fund late-stage clinical costs without partners.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt Reduction
A dramatic reduction in debt materially lowers interest and covenant pressure and improves financing optionality. Over a multi-month horizon this reduces near-term solvency risk, extends strategic runway for clinical programs, and makes non-dilutive partnership or licensing deals easier to negotiate.
Read all positive factors
AB Science SA (AB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€39.63M
Dividend YieldN/A
Average Volume (3M)323.75K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth9.51%
EPS Growth73.33%
CountryFR
Employees40
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding73,251,990
10 Day Avg. Volume89,975
30 Day Avg. Volume323,750
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€1.20M
AB Science SA Business Overview & Revenue Model
Company Description
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhi...
How the Company Makes Money
null...
AB Science SA Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 1.07M | 970.00K | 958.00K | 1.61M |
| Gross Profit | 720.00K | 1.25M | 587.00K | 927.00K | 1.50M |
| EBITDA | -1.22M | -4.92M | -12.80M | -13.41M | -17.36M |
| Net Income | -1.56M | -7.83M | -10.05M | -13.62M | -14.46M |
Balance Sheet | |||||
| Total Assets | 24.52M | 23.18M | 25.50M | 23.84M | 21.27M |
| Cash, Cash Equivalents and Short-Term Investments | 10.18M | 7.99M | 6.07M | 7.27M | 8.72M |
| Total Debt | 4.24M | 18.47M | 19.10M | 23.96M | 8.35M |
| Total Liabilities | 34.34M | 46.93M | 46.51M | 59.51M | 44.47M |
| Stockholders Equity | -17.20M | -23.75M | -21.01M | -35.67M | -23.20M |
Cash Flow | |||||
| Free Cash Flow | -4.57M | 370.00K | -17.22M | -18.11M | -17.74M |
| Operating Cash Flow | -4.29M | 525.00K | -16.87M | -17.47M | -17.18M |
| Investing Cash Flow | -224.00K | -136.00K | -614.00K | -360.00K | -590.00K |
| Financing Cash Flow | 6.69M | 1.53M | 16.27M | 16.39M | 5.84M |
AB Science SA Technical Analysis
Neutral
0.51
Price Trends
0.77
Negative
0.94
Negative
1.11
Negative
Market Momentum
-0.06
Negative
48.76
Neutral
50.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Neutral. The current price of 0.51 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.77, and below the 200-day MA of 1.11, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 48.76 is Neutral, neither overbought nor oversold. The STOCH value of 50.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:AB.
AB Science SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €89.99B | 22.77 | 10.51% | 5.42% | 15.30% | -35.58% | |
67 Neutral | €13.83B | 26.97 | 10.36% | 1.01% | 13.63% | 14.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €143.67M | -2.78 | 593.93% | ― | -77.92% | 11.11% | |
43 Neutral | €178.50M | -4.22 | -80.61% | ― | 32.62% | -7.59% | |
42 Neutral | €39.63M | -13.77 | 6.99% | ― | 9.51% | 73.33% | |
42 Neutral | €75.43M | -1.90 | -96.73% | ― | -96.25% | -197.89% |
* Healthcare Sector Average
FR:AB
AB Science SA
0.70
-0.58
-45.41%
FR:IPH
Innate Pharma SA
1.53
-0.30
-16.17%
FR:IPN
Ipsen
159.70
55.51
53.27%
FR:OSE
OSE Immunotherapeutics SA
3.26
-2.78
-46.04%
FR:SAN
Sanofi
74.50
-0.95
-1.26%
FR:ALCLS
Cellectis SA
2.48
0.17
7.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.